Rxo (RXO) Total Liabilities (2021 - 2026)

Rxo (RXO) has 6 years of Total Liabilities data on file, last reported at $1.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 2.45% year-over-year to $1.8 billion; the trailing twelve-month figure through Mar 2026 stood at $1.8 billion (up 2.45% YoY), and the FY2025 full-year result was $1.7 billion, down 3.66% from the prior year.
• Total Liabilities for Q1 2026 stood at $1.8 billion, up from $1.7 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $1.8 billion in Q4 2024 and bottomed at -$1.2 billion in Q2 2022.
• The 5-year median for Total Liabilities is $1.4 billion (2023), against an average of $1.2 billion.
• The widest annual swing landed in 2023, when Total Liabilities surged 237.39%; it then slipped 15.07% in 2024.
• A 5-year view of Total Liabilities shows it stood at $1.4 billion in 2022, then retreated by 14.75% to $1.2 billion in 2023, then jumped by 46.39% to $1.8 billion in 2024, then retreated by 3.66% to $1.7 billion in 2025, then rose by 1.32% to $1.8 billion in 2026.
• The last three Total Liabilities figures came in at $1.8 billion (Q1 2026), $1.7 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.

Peer Comparison